- Home
- ESAB vs RGEN Comparison
ESAB vs RGEN Comparison
Compare ESAB & RGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | RGEN |
|---|---|---|
| Founded | 1904 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 8.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ESAB | RGEN |
|---|---|---|
| Price | $112.44 | $164.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $140.38 | ★ $174.90 |
| AVG Volume (30 Days) | 465.1K | ★ 552.2K |
| Earning Date | 02-19-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.95 | 0.03 |
| Revenue | ★ $2,792,325,000.00 | $707,890,000.00 |
| Revenue This Year | $3.25 | $17.84 |
| Revenue Next Year | $8.37 | $12.44 |
| P/E Ratio | ★ $25.18 | $5,323.01 |
| Revenue Growth | 1.19 | ★ 11.74 |
| 52 Week Low | $100.17 | $102.97 |
| 52 Week High | $135.84 | $182.52 |
Technical Indicators
Market Signals| Indicator | ESAB | RGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 53.91 |
| Support Level | $111.25 | $161.41 |
| Resistance Level | $114.80 | $167.65 |
| Average True Range (ATR) | 2.42 | 4.61 |
| MACD | -0.17 | -0.11 |
| Stochastic Oscillator | 17.19 | 68.88 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About RGEN Repligen Corporation
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.